PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100
Go back to PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100| (NASDAQ: JUNS) | Delayed: 0.23 -0.01 (4.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.24 | 52 Week High | $ | |||
| Open | $0.24 | 52 Week Low | $ | |||
| Day High | $0.24 | P/E | N/A | |||
| Day Low | $0.23 | EPS | $ | |||
| Volume | 935,809 | |||||
| Medmark Group Inc New (AMEX: MDMA) | Delayed: 0.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.00 | 52 Week High | $0.00 | |||
| Open | $0.00 | 52 Week Low | $0.00 | |||
| Day High | $0.00 | P/E | N/A | |||
| Day Low | $0.00 | EPS | $0.00 | |||
| Volume | 0 | |||||
| (AMEX: MDXXF) | Delayed: 0.11 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.11 | 52 Week High | $ | |||
| Open | $0.11 | 52 Week Low | $ | |||
| Day High | $0.11 | P/E | N/A | |||
| Day Low | $0.11 | EPS | $ | |||
| Volume | 2,450 | |||||
